According to Luming Liu, M. D., chair and Zhiqiang Meng, deputy-chair of the Department of Integrative Medicine at Fudan University Cancer Hospital, the ongoing collaboration with Cohen and M. D. Anderson has opened multiple avenues for research training. Currently faculty and staff from both institutions are supporting the collaboration through work on several research projects.
Joint clinical studies currently underway include examining the ability of HuaChanSu (a form of dried toad venom) to treat advanced pancreatic, liver and lung cancer. Energy-based practices such as qigong are also being investigated as a way to promote relaxation among breast cancer patients undergoing radiation therapy.
"Dr. Cohen and the researchers in Shanghai have championed a 21st century research program dedicated to studying the mainstays of traditional Chinese medicine and its application to cancer," said John Mendelsohn, M.D., president of M. D. Anderson. "Their continued work in this area exemplifies our commitment to the exchange of knowledge across continents to benefit cancer research and treatment."
Traditional Chinese medicine dates back up to 5,000 years ago and in China is accepted as standard of care. The majority of chemotherapies used today originated from natural plants and many popular drugs, such as morphine and aspirin were derived from plants, according to Cohen.
At M. D. Anderson, Cohen said that over 50 percent of patients report that they use ingestible complementary therapies. "Growing numbers of patients globally are integrating complementary therapies into their cancer care, especially cancer survivors who are looking to Eastern medicine to manage side effects and even prevent recurrence," Cohen said. "It is important for medical teams to understand f
'/>"/>
| Contact: Laura Sussman lsussman@mdanderson.org 713-745-2457 University of Texas M. D. Anderson Cancer Center Source:Eurekalert |